Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin

Diabetes Care

Volumn 37, Issue 9, 2014, Pages 2435-2441

  Raz, Itamar ^a   Bhatt, Deepak L ^b   Hirshberg, Boaz ^c   Mosenzon, Ofri ^a   Scirica, Benjamin M ^b   Umez Eronini, Amarachi ^b   Im, Kyungah ^b   Stahre, Christina ^d   Buskila, Alona ^a   Iqbal, Nayyar ^e   Greenberger, Norton ^b   Lerch, Markus M ^f  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e BRISTOL MYERS SQUIBB   (United States)

^f UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE PANCREATITIS; ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CAUSE OF DEATH; CHRONIC PANCREATITIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; INTERNATIONAL COOPERATION; INTERVENTION STUDY; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROGNOSIS;

ADAMANTANE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERNATIONAL AGENCIES; INTERVENTION STUDIES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROGNOSIS; RISK FACTORS;

EID: 84905403704     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2546     Document Type: Article

References (35)

1. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care 2009;32:834-838
2. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
3. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretinbased therapies: Are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125
4. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-1027
5. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1- based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus a population-based matched case-control study. JAMA Intern Med 2013;173:534-539
6. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126-2132
7. Gonzalez-Perez A, Schlienger RG, Rodŕiguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: A populationbased cohort study. Diabetes Care 2010;33: 2580-2585
8. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-990
9. Bonner-Weir S, In't Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab. In press
10. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitusdevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [article online], 2008. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 19 January 2011
11. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 2011; 34(Suppl. 2):S101-S106
12. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
13. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
14. Rosenstock J, Marx N, Kahn SE, et al. Rationale and design of the CAROLINA trial: An active comparator CARdiOvascular Outcome Study of the DPP-4 Inhibitor LINAgliptin in Patients with Type 2 Diabetes At High Cardiovascular risk (Abstract). Diabetes 2011;60(Suppl. 1):A303
15. Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (Abstract). Available from http://professional. diabetes.org/Abstracts-Display.aspx?TYP= 1&CID=74327. Accessed 1 October 2013
16. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818-825
17. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417-426
18. Banks PA, Bollen TL, Dervenis C, et al.; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitisd2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102-111
19. Lerch MM. Classifying an unpredictable disease: The revised Atlanta classification of acute pancreatitis. Gut 2013;62:2-3
20. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993;128:586-590
21. Malloy J, Gurney K, Shan K, Yan P, Chen S. Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:419-424
22. Tokuyama H, Kawamura H, Fujimoto M, et al. A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes. Diabetes Res Clin Pract 2013;100:e66-e69
23. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-1685
24. Mart́inez J, Johnson CD, Śanchez-Paýa J, de Madaria E, Robles-D́iaz G, Ṕerez-Mateo M. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: An updated meta-analysis. Pancreatology 2006;6: 206-209
25. Bexelius TS, Ljung R, Mattsson F, Lagergren J. Cardiovascular disease and risk of acute pancreatitis in a population-based study. Pancreas 2013;42:1011-1015
26. Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-induced pancreatitis. Curr Gastroenterol Rep 2012;14:131-138
27. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13: 559-566
28. Mayerle J, Hoffmeister A, Werner J, Witt H, Lerch MM, Mössner J. Chronic pancreatitisd definition, etiology, investigation and treatment. Dtsch Arztebl Int 2013;110:387-393
29. Lowenfels AB, Maisonneuve P, Cavallini G, et al.; International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-1437
30. Ekbom A, McLaughlin JK, Karlsson BM, et al. Pancreatitis and pancreatic cancer: A populationbased study. J Natl Cancer Inst 1994;86:625-627
31. Duell EJ, Lucenteforte E, Olson SH, et al. Pancreatitis and pancreatic cancer risk: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012;23:2964-2970
32. Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137:482-488
33. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52: 1766-1777
34. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-989
35. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10:289-301